Back

Laminin Receptor Characterization in Acute Myeloid Leukemia: Integrin α7β1 Defines non-Leukemic Stem Cells with Migratory Potential

Goersch, E.; Arnone, M.; Klimiankou, M.; Weller, J.; Rudat, S.; Klein, G.; Lengerke, C.

2024-04-01 cancer biology
10.1101/2024.03.29.587290 bioRxiv
Show abstract

Interactions with the bone marrow (BM) niche are crucial for promoting self-renewal and survival of acute myeloid leukemia (AML) cells. Consequently, AML cells express a variety of surface receptors to engage with BM niche cells and extracellular matrix proteins, including laminins. Despite the association of laminin receptor expression with stemness in healthy hematopoiesis, the role of laminin receptors in AML remains poorly understood. In this study, we present a comprehensive examination of the laminin receptors integrin 3{beta}1, 6{beta}1, 7{beta}1 and basal cell adhesion molecule (BCAM) in AML. We demonstrate that high mRNA expression of all four laminin receptors correlates with poor overall survival. Notably, integrin 6 and 7 display the highest cell surface presentation among the examined laminin receptors and are higher expressed on AML cells compared to healthy controls. Moreover, our results indicate that integrin 7 expression allows to distinguish between leukemic stem cells (LSC) and non-LSC populations. Specifically, integrin 7 appears to mark non-LSC with enhanced migratory potential. Together, our results confirm the association of high laminin receptor expression with poor prognosis and establish integrin 7 as marker of high migratory non-LSC. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=128 SRC="FIGDIR/small/587290v1_ufig1.gif" ALT="Figure 1"> View larger version (46K): org.highwire.dtl.DTLVardef@bdcc20org.highwire.dtl.DTLVardef@a45fd2org.highwire.dtl.DTLVardef@18f058forg.highwire.dtl.DTLVardef@b613fc_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Experimental Hematology
11 papers in training set
Top 0.1%
15.1%
2
Cancers
200 papers in training set
Top 0.5%
8.6%
3
Cells
232 papers in training set
Top 0.1%
7.0%
4
Blood Advances
54 papers in training set
Top 0.2%
6.5%
5
Leukemia
39 papers in training set
Top 0.2%
5.0%
6
Blood
67 papers in training set
Top 0.3%
5.0%
7
Haematologica
24 papers in training set
Top 0.1%
4.4%
50% of probability mass above
8
PLOS ONE
4510 papers in training set
Top 38%
3.7%
9
Scientific Reports
3102 papers in training set
Top 41%
3.1%
10
International Journal of Molecular Sciences
453 papers in training set
Top 5%
2.1%
11
Biomedicines
66 papers in training set
Top 0.4%
2.1%
12
British Journal of Haematology
15 papers in training set
Top 0.2%
2.1%
13
Journal of Leukocyte Biology
40 papers in training set
Top 0.1%
2.1%
14
Frontiers in Physiology
93 papers in training set
Top 2%
1.9%
15
Frontiers in Oncology
95 papers in training set
Top 2%
1.5%
16
Frontiers in Immunology
586 papers in training set
Top 5%
1.4%
17
Clinical Epigenetics
53 papers in training set
Top 0.7%
1.3%
18
Blood Cancer Journal
11 papers in training set
Top 0.2%
1.3%
19
Molecular Cancer Research
42 papers in training set
Top 0.5%
1.0%
20
Molecular Oncology
50 papers in training set
Top 0.7%
1.0%
21
Laboratory Investigation
13 papers in training set
Top 0.2%
0.9%
22
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.6%
0.8%
23
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 8%
0.8%
24
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.8%
0.8%
25
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 43%
0.8%
26
Oncogenesis
12 papers in training set
Top 0.1%
0.8%
27
Clinical and Translational Medicine
30 papers in training set
Top 1.0%
0.8%
28
Journal of Clinical Medicine
91 papers in training set
Top 7%
0.7%
29
OncoImmunology
22 papers in training set
Top 0.4%
0.7%
30
Oncogene
76 papers in training set
Top 2%
0.7%